Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update By: MiNK Therapeutics via GlobeNewswire July 28, 2023 at 08:30 AM EDT Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release before the market opens on Thursday, Aug. 10. In addition, MiNK Chief Executive Officer and President Jennifer Buell, Ph.D., will participate in and provide an update on the progress of the company’s portfolio at the following upcoming investor conference: BTIG Virtual Biotechnology Conference 2023 – A fireside chat will be held virtually on Tuesday, Aug. 8, at 11:30 a.m. ET. A replay of the fireside chat from the BTIG conference will be accessible on the company’s website at https://investor.minktherapeutics.com/events-and-presentations following the event. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, New York. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT. Investor Contact Zack Armen 917-362-1370 investors@minktherapeutics.com Media Contact Alexa Buffa 781-674-4428 communications@minktherapeutics.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update By: MiNK Therapeutics via GlobeNewswire July 28, 2023 at 08:30 AM EDT Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release before the market opens on Thursday, Aug. 10. In addition, MiNK Chief Executive Officer and President Jennifer Buell, Ph.D., will participate in and provide an update on the progress of the company’s portfolio at the following upcoming investor conference: BTIG Virtual Biotechnology Conference 2023 – A fireside chat will be held virtually on Tuesday, Aug. 8, at 11:30 a.m. ET. A replay of the fireside chat from the BTIG conference will be accessible on the company’s website at https://investor.minktherapeutics.com/events-and-presentations following the event. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, New York. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT. Investor Contact Zack Armen 917-362-1370 investors@minktherapeutics.com Media Contact Alexa Buffa 781-674-4428 communications@minktherapeutics.com
Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release before the market opens on Thursday, Aug. 10. In addition, MiNK Chief Executive Officer and President Jennifer Buell, Ph.D., will participate in and provide an update on the progress of the company’s portfolio at the following upcoming investor conference: BTIG Virtual Biotechnology Conference 2023 – A fireside chat will be held virtually on Tuesday, Aug. 8, at 11:30 a.m. ET. A replay of the fireside chat from the BTIG conference will be accessible on the company’s website at https://investor.minktherapeutics.com/events-and-presentations following the event. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, New York. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT. Investor Contact Zack Armen 917-362-1370 investors@minktherapeutics.com Media Contact Alexa Buffa 781-674-4428 communications@minktherapeutics.com
